[Chronic graft versus host disease (GvHD): causes, manifestation, diagnosis and treatment option].
GvHD is the reaction of donor T lymphocytes against recipient tissues induced by inflammation. Two forms of GvHD manifest acutely early after transplant and chronic within the first year mimicking the full spectrum of autoimmune disease. Manifestation and severity depend on patient-, donor-, disease- and transplant-related factors. Primary therapy are systemic (Prednison 0,5-1 mg/kg KG/d) and topical glucocorticoids. There is no established standard for 2nd line therapy. Avoidance of longer exposure to steroids and of opportunistic infections are imminently important.
Abteilung Hämatologie und Onkologie, Medizinische Klinik, Universitätsklinik Freiburg. juergen.finke@uniklinik-freiburg.de
J
J
Finke
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002908:Chronic Disease; D005938:Glucocorticoids / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D011241:Prednisone / Q000627:therapeutic use*; D019737:Transplants / Q000009:adverse effects*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011241:Prednisone